Structure Therapeutics (GPCR) Research & Development (2022 - 2026)
Quarterly Research & Development rose 55.15% to $66.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $248.9 million through Mar 2026, up 89.99% year-over-year, with the annual reading at $225.3 million for FY2025, 107.01% up from the prior year.
Structure Therapeutics' Research & Development history spans 5 years, with the latest figure at $66.5 million for Q1 2026.
- Research & Development came in at $66.5 million for Q1 2026, down from $68.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $68.7 million in Q4 2025 to a low of $8.4 million in Q4 2022.
- The 5-year median for Research & Development is $20.7 million (2024), against an average of $29.8 million.
- Year-over-year, Research & Development grew 13.6% in 2024 and then skyrocketed 148.12% in 2025.
- Structure Therapeutics' Research & Development stood at $8.4 million in 2022, then surged by 139.74% to $20.0 million in 2023, then soared by 67.08% to $33.5 million in 2024, then skyrocketed by 105.12% to $68.7 million in 2025, then decreased by 3.18% to $66.5 million in 2026.
- Per Business Quant, the three most recent readings for GPCR's Research & Development are $66.5 million (Q1 2026), $68.7 million (Q4 2025), and $59.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 1.54 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -2.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Structure Therapeutics | 8.43 Bn | 8.43 Bn | - | 66.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.51 Mn |
| Dec 31, 2025 | 68.69 Mn |
| Sep 30, 2025 | 58.99 Mn |
| Jun 30, 2025 | 54.71 Mn |
| Mar 31, 2025 | 42.87 Mn |
| Dec 31, 2024 | 33.49 Mn |
| Sep 30, 2024 | 32.60 Mn |
| Jun 30, 2024 | 22.05 Mn |
| Mar 31, 2024 | 20.68 Mn |
| Dec 31, 2023 | 20.04 Mn |
| Sep 30, 2023 | 17.52 Mn |
| Jun 30, 2023 | 19.41 Mn |
| Mar 31, 2023 | 13.14 Mn |
| Dec 31, 2022 | 8.36 Mn |
| Sep 30, 2022 | 9.16 Mn |
| Jun 30, 2022 | 10.18 Mn |
| Mar 31, 2022 | 8.49 Mn |